Plain-English translation of NCT06498635 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The INSIGHT trial is testing whether a medication called , given after surgery for early-stage lung cancer, can help prevent cancer from coming back in people whose tumors have completely disappeared. You've already received chemotherapy and immunotherapy before surgery and had complete surgical removal of your cancer. This study will randomly assign you to either continue with the medication for up to a year, or to be monitored closely without additional treatment.
Even when doctors remove all visible cancer during surgery, some patients experience cancer returning months or years later. This trial is designed to find out whether continuing with immunotherapy after surgery can reduce the risk of recurrence and help patients live longer and healthier lives.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll be randomly assigned to one of two groups. One group will receive the medication as an infusion (through an IV) once every four weeks for up to one year; the other group will have regular monitoring with CT scans and blood tests but no additional medication. Either way, you'll have CT scans and blood work done throughout the year, and you'll complete questionnaires about how you're feeling and any side effects. The study lasts about one year from the time you're enrolled.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States